Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (291-300 of 346) with videos related to

Pageof 35
Sort By:
Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Blood|March 29, 2024
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLYaqi Zhao, Nicholas J Short, Hagop M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLYaqi Zhao, Nicholas J Short, Hagop M Kantarjian, et al.
NEJM Evidence|February 6, 2024
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDSKoji Sasaki, Elias Jabbour, Guillermo Montalban-Bravo, et al.
Cancers|April 13, 2023
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center ExperienceAdriana Trabal, Amber Gibson, Jiasen He, et al.
American Journal of Hematology|March 1, 2020
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Caleb A Class, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Nuclear Phase Separation Drives NPM1-mutant Acute Myeloid LeukemiaGandhar K Datar, Elmira Khabusheva, Archish Anand, et al.
Pageof 35

Showing results (291-300 of 346) with videos related to

Sort By:
Pageof 35
Blood Advances|May 9, 2022
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapseNicholas J Short, Hagop Kantarjian, Farhad Ravandi, et al.
Leukemia & Lymphoma|April 20, 2022
A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemiaNicholas J Short, Gautam Borthakur, Naveen Pemmaraju, et al.
Blood Advances|March 8, 2023
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensityAlexandre Bazinet, Tapan Kadia, Nicholas J Short, et al.
Blood|March 29, 2024
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLYaqi Zhao, Nicholas J Short, Hagop M Kantarjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2024
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AMLNicholas J Short, Naval Daver, Courtney D Dinardo, et al.
Medrxiv : the Preprint Server for Health Sciences|December 18, 2023
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLYaqi Zhao, Nicholas J Short, Hagop M Kantarjian, et al.
NEJM Evidence|February 6, 2024
Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDSKoji Sasaki, Elias Jabbour, Guillermo Montalban-Bravo, et al.
Cancers|April 13, 2023
Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center ExperienceAdriana Trabal, Amber Gibson, Jiasen He, et al.
American Journal of Hematology|March 1, 2020
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapyGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Caleb A Class, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Nuclear Phase Separation Drives NPM1-mutant Acute Myeloid LeukemiaGandhar K Datar, Elmira Khabusheva, Archish Anand, et al.
Pageof 35